loading
Precedente Chiudi:
$2.35
Aprire:
$2.34
Volume 24 ore:
3.06M
Relative Volume:
1.51
Capitalizzazione di mercato:
$175.80M
Reddito:
$32.31M
Utile/perdita netta:
$-237.09M
Rapporto P/E:
-0.7708
EPS:
-2.88
Flusso di cassa netto:
$-219.11M
1 W Prestazione:
+12.69%
1M Prestazione:
+35.37%
6M Prestazione:
+69.47%
1 anno Prestazione:
-55.95%
Intervallo 1D:
Value
$2.15
$2.385
Intervallo di 1 settimana:
Value
$1.935
$2.55
Portata 52W:
Value
$0.9101
$6.05

Editas Medicine Inc Stock (EDIT) Company Profile

Name
Nome
Editas Medicine Inc
Name
Telefono
617-401-9000
Name
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Name
Dipendente
226
Name
Cinguettio
@editasmed
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
EDIT's Discussions on Twitter

Confronta EDIT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
EDIT
Editas Medicine Inc
2.22 175.80M 32.31M -237.09M -219.11M -2.88
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.87 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
509.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
309.70 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.08 28.51B 3.81B -644.79M -669.77M -6.24

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-28 Iniziato H.C. Wainwright Buy
2024-12-16 Downgrade JP Morgan Neutral → Underweight
2024-12-13 Downgrade Chardan Capital Markets Buy → Neutral
2024-12-13 Downgrade Stifel Buy → Hold
2024-12-13 Downgrade Truist Buy → Hold
2024-12-11 Downgrade Wells Fargo Overweight → Equal Weight
2024-11-25 Downgrade BofA Securities Buy → Underperform
2024-11-06 Aggiornamento Evercore ISI In-line → Outperform
2024-11-04 Downgrade Raymond James Outperform → Mkt Perform
2024-08-08 Aggiornamento BofA Securities Neutral → Buy
2024-05-09 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-10-24 Aggiornamento Citigroup Neutral → Buy
2023-10-18 Aggiornamento JP Morgan Underweight → Neutral
2023-10-17 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-09-29 Aggiornamento Stifel Hold → Buy
2023-06-12 Aggiornamento Raymond James Mkt Perform → Outperform
2023-02-01 Iniziato Cantor Fitzgerald Overweight
2022-12-13 Iniziato Citigroup Neutral
2022-12-06 Ripresa Credit Suisse Neutral
2022-11-18 Downgrade Credit Suisse Outperform → Neutral
2022-11-18 Downgrade Oppenheimer Outperform → Perform
2022-09-29 Iniziato BofA Securities Neutral
2021-10-19 Iniziato SVB Leerink Mkt Perform
2021-09-24 Iniziato Stifel Hold
2021-09-10 Aggiornamento Oppenheimer Perform → Outperform
2021-08-09 Aggiornamento Truist Hold → Buy
2021-08-05 Aggiornamento Evercore ISI Underperform → Outperform
2021-06-04 Ripresa Robert W. Baird Outperform
2021-05-04 Iniziato RBC Capital Mkts Sector Perform
2021-04-16 Iniziato Goldman Sell
2021-03-22 Iniziato Credit Suisse Outperform
2021-03-01 Downgrade Barclays Overweight → Equal Weight
2021-02-26 Downgrade Truist Buy → Hold
2021-01-19 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-01-07 Downgrade Raymond James Outperform → Mkt Perform
2020-12-10 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-11-03 Iniziato Robert W. Baird Underperform
2020-06-18 Ripresa SunTrust Buy
2020-02-21 Iniziato Wells Fargo Equal Weight
2019-04-12 Iniziato Evercore ISI Outperform
2018-10-10 Iniziato Guggenheim Neutral
2018-09-21 Iniziato Raymond James Outperform
2018-05-15 Reiterato Chardan Capital Markets Buy
2018-02-13 Iniziato CLSA Underperform
2018-01-23 Aggiornamento SunTrust Hold → Buy
2017-07-14 Iniziato SunTrust Hold
2017-03-28 Iniziato Chardan Capital Markets Buy
2016-08-10 Aggiornamento Jefferies Hold → Buy
2016-06-02 Iniziato Jefferies Hold
2016-02-29 Iniziato JMP Securities Mkt Outperform
2016-02-29 Iniziato JP Morgan Neutral
2016-02-29 Iniziato Morgan Stanley Equal-Weight
Mostra tutto

Editas Medicine Inc Borsa (EDIT) Ultime notizie

pulisher
Jun 19, 2025

Cancer Gene Therapy Market Set to Soar: Breakthrough - openPR.com

Jun 19, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - AOL.com

Jun 17, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 17, 2025

Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat

Jun 17, 2025
pulisher
Jun 14, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Position Trimmed by Bank of America Corp DE - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Analysts Offer Predictions for Editas Medicine FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Editas Medicine (EDIT) Unveils Promising Gene Editing Data for B - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Kalkine: Editas Medicine’s In Vivo Gene Editing Progress Unveiled at EHA 2025 with tLNP Approach - Kalkine Media

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hema - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method - Nasdaq

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - The Manila Times

Jun 12, 2025
pulisher
Jun 12, 2025

Breakthrough: New Gene Editing Therapy Achieves 58% Success Rate for Sickle Cell Disease Treatment - Stock Titan

Jun 12, 2025
pulisher
Jun 11, 2025

Why Is Editas (EDIT) Up 40% Since Last Earnings Report? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 09, 2025

Ameriprise Financial Inc. Has $289,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 09, 2025
pulisher
Jun 08, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $26,130.24 in Stock - MarketBeat

Jun 08, 2025
pulisher
Jun 07, 2025

Zacks Research Raises Earnings Estimates for Editas Medicine - MarketBeat

Jun 07, 2025
pulisher
Jun 05, 2025

Two Sigma Investments LP Increases Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 05, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Has $3.49 Million Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 05, 2025
pulisher
Jun 04, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Down 21.7% in May - MarketBeat

Jun 04, 2025
pulisher
Jun 02, 2025

editas medicine amends stock plan and increases authorized shares - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Editas Medicine Stockholders Approve Key Amendments - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

editas medicine amends stock plan and increases authorized shares By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 01, 2025

Two Sigma Advisers LP Increases Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io

Jun 01, 2025
pulisher
May 31, 2025

Millennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World

May 31, 2025
pulisher
May 30, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by BNP Paribas Financial Markets - Defense World

May 30, 2025
pulisher
May 30, 2025

Northern Trust Corp Has $884,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World

May 30, 2025
pulisher
May 28, 2025

Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Editas Medicine (EDIT) Joins Russell Microcap Index - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com

May 28, 2025
pulisher
May 26, 2025

Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges By Investing.com - Investing.com Canada

May 26, 2025
pulisher
May 26, 2025

Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges - Investing.com Australia

May 26, 2025
pulisher
May 25, 2025

1 Stock Down 97% That Could Double, According to Wall Street - AOL.com

May 25, 2025
pulisher
May 24, 2025

Tang Capital Management LLC Purchases Shares of 400,000 Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 24, 2025
pulisher
May 23, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages - Defense World

May 23, 2025
pulisher
May 22, 2025

Jacobs Levy Equity Management Inc. Has $900,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 22, 2025
pulisher
May 21, 2025

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28% - simplywall.st

May 21, 2025

Editas Medicine Inc Azioni (EDIT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Editas Medicine Inc Azioni (EDIT) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Jun 03 '25
Sale
1.72
726
1,252
69,519
O'Neill Gilmore Neil
CEO
Jun 03 '25
Sale
1.72
15,192
26,196
280,282
$21.16
price down icon 1.86%
$34.86
price down icon 0.14%
$20.56
price up icon 1.98%
$102.68
price up icon 3.24%
$106.53
price up icon 2.04%
biotechnology ONC
$247.08
price down icon 2.25%
Capitalizzazione:     |  Volume (24 ore):